Is it safe?
Can BMY take a bad year?
Bristol Myers Squibb carries $32.8B of net debt at 2.38× EBITDA: a load its earnings can carry.
$32.8B
Net debt · as at Q2 2026 · under two and a half years of EBITDA, comfortable
- Net debt / EBITDA
- 2.38×
Net debt / EBITDA · 4.08× a year ago · the load is coming down
- Interest cover
- 6.88×
Interest cover · operating profit covers the interest bill several times over
- Annualised volatility
- 28%
Annualised volatility · about as steady as the market itself
Details›
- Total debtQ2 2026
- $43.9B
- Cash and short-term investments
- $11.1B
- Net debt
- $32.8B
- EBITDA, trailing twelve months
- $13.8B
- Operating profit, trailing twelve months
- $11.9B
- Debt / equity
- 1.97×
- Total debt / EBITDA
- 3.19×
- Annualised volatilitytwo years of daily moves
- 28%
- Worst drawdown on file
- −48%
- Below its 52-week high
- −0.52%
Balance sheet from SEC filings; drawdown and volatility from end-of-day closes; Altman Z from the filed statements.
Drug Manufacturers - General
Ranks #7 of 16 by Smart Score